Meldrum D R, Cain B S, Meng X, Cleveland J C, Shames B D, Donnahoo K K, Banerjee A, Harken A H
Department of Surgery, University of Colorado Health Sciences Center, Denver, Colorado, 80262, USA.
J Surg Res. 1999 Jul;85(1):77-82. doi: 10.1006/jsre.1999.5671.
Recent evidence has implicated the KATP channel as an important mediator of ischemic preconditioning (IPC). Indeed, patients taking oral sulfonylurea hypoglycemic agents (i.e., KATP channel inhibitors) for treatment of diabetes mellitus are resistant to the otherwise profoundly protective effects of IPC. Unfortunately, many cardiopulmonary bypass patients, who may benefit from IPC, are chronically exposed to these agents. Calcium preconditioning (CPC) is a potent form of similar myocardial protection which may or may not utilize the KATP channel in its mechanism of protection. The purpose of this study was to determine whether CPC may bypass the KATP channel in its mechanism of action. If so, CPC may offer an alternative to IPC in patients chronically exposed to these agents.
Isolated rat hearts (n = 6-8/group) were perfused (Langendorff) and received KATP channel inhibition (glibenclamide) or saline vehicle 10 min prior to either a CPC or IPC preconditioning stimulus or neither (ischemia and reperfusion, I/R). Hearts were subjected to global warm I/R (20 min/40 min). Postischemic myocardial functional recovery was determined by measuring developed pressure (DP), coronary flow (CF), and compliance (end diastolic pressure, EDP) with a MacLab pressure digitizer.
Both CPC and IPC stimuli protected myocardium against postischemic dysfunction (P < 0.05 vs I/R; ANOVA with Bonferroni/Dunn): DP increased from 52 +/- 4 (I/R) to 79 +/- 2 and 83 +/- 4 mmHg; CF increased from 11 +/- 0.7 to 17 +/- 2 and 16 +/- 1 ml/min; and EDP decreased (compliance improved) from 50 +/- 7 to 27 +/- 5 and 31 +/- 7 mmHg. However, KATP channel inhibition abolished protection in hearts preconditioned with IPC (P < 0.05 vs IPC alone), but not in those preconditioned with CPC (P > 0.05 vs CPC alone).
(1) Both IPC and CPC provide similar myocardial protection; (2) IPC and CPC operate via different mechanisms; i.e., IPC utilizes the KATP channel whereas CPC does not; and (3) CPC may offer a means of bypassing the deleterious effects of KATP channel inhibition in diabetic patients chronically exposed to oral sulfonylurea hypoglycemic agents.
最近的证据表明,ATP敏感性钾通道(KATP通道)是缺血预处理(IPC)的重要介质。实际上,服用口服磺脲类降糖药(即KATP通道抑制剂)治疗糖尿病的患者对IPC原本具有的显著保护作用具有抗性。不幸的是,许多可能从IPC中获益的体外循环患者长期接触这些药物。钙预处理(CPC)是一种类似的有效心肌保护形式,其保护机制可能利用也可能不利用KATP通道。本研究的目的是确定CPC在其作用机制中是否可以绕过KATP通道。如果是这样,CPC可能为长期接触这些药物的患者提供一种替代IPC的方法。
将离体大鼠心脏(每组n = 6 - 8)进行Langendorff灌注,并在进行CPC或IPC预处理刺激前10分钟给予KATP通道抑制(格列本脲)或生理盐水,或者不进行预处理(缺血再灌注,I/R)。心脏接受整体温缺血再灌注(20分钟/40分钟)。缺血后心肌功能恢复通过使用MacLab压力数字化仪测量左心室发展压(DP)、冠状动脉血流量(CF)和顺应性(舒张末期压力,EDP)来确定。
CPC和IPC刺激均能保护心肌免受缺血后功能障碍的影响(与I/R相比,P < 0.05;采用Bonferroni/Dunn法进行方差分析):DP从52±4(I/R)增加到79±2和83±4 mmHg;CF从11±0.7增加到17±2和16±1 ml/min;EDP从50±7降低(顺应性改善)到27±5和31±7 mmHg。然而,KATP通道抑制消除了IPC预处理心脏的保护作用(与单独IPC相比,P < 0.05),但未消除CPC预处理心脏的保护作用(与单独CPC相比,P > 0.05)。
(1)IPC和CPC均提供类似的心肌保护;(2)IPC和CPC通过不同机制起作用,即IPC利用KATP通道,而CPC不利用;(3)CPC可能为长期接触口服磺脲类降糖药的糖尿病患者提供一种绕过KATP通道抑制有害作用的方法。